Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-mutant Mice

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2005 Jul 20

PMID 16027259

Citations 95

Authors

Yanli Song

John E Jones

Hideyuki Beppu

John F Keaney Jr

Joseph Loscalzo

Ying-Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Bone morphogenetic protein receptor-2 (BMPR2)-heterozygous, mutant (BMPR2(+/-)) mice have a genetic trait similar to that of certain patients with idiopathic pulmonary arterial hypertension (IPAH). To understand the role of BMPR2 in the development of IPAH, we examined the phenotype of BMPR2(+/-) mice and their response to inflammatory stress.

Methods And Results: BMPR2(+/-) mice were found to have the same life span, right ventricular systolic pressure (RVSP), and lung histology as those of wild-type mice under unstressed conditions. However, when treated with recombinant adenovirus expressing 5-lipoxygenase (Ad5LO), BMPR2(+/-) mice exhibited significantly higher RVSP than wild-type mice. The increase of RVSP occurred in the first 2 weeks after Ad5LO delivery. Modest but significant muscularization of distal pulmonary arterioles appeared in BMPR2(+/-) mice 4 weeks after Ad5LO treatment. Measurement of urinary metabolites of vasoactive molecules showed that cysteinyl leukotrienes, prostacyclin metabolites, and PGE2 were all increased to a similar degree in both BMPR2(+/-) and wild-type mice during 5LO transgene expression, whereas urinary endothelin-1 remained undetectable. Urinary thromboxane A2 metabolites, in contrast, were significantly higher in BMPR2(+/-) than in wild-type mice and paralleled the increase in RVSP. Platelet activation markers, serotonin, and soluble P-selectin showed a trend toward higher concentrations in BMPR2(+/-) than wild-type mice. Cell culture studies found that BMP treatment reduced interleukin-1beta-stimulated thromboxane A2 production in the pulmonary epithelial cell line A549.

Conclusions: BMPR2(+/-) mice do not develop pulmonary hypertension spontaneously; however, under inflammatory stress, they are more susceptible to an increase in RVSP, thromboxane A2 production, and vascular remodeling than wild-type mice.

Citing Articles

ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport.

Liu B, Azfar M, Legchenko E, West J, Martin S, Van den Haute C Cardiovasc Res. 2024; 120(7):756-768.

PMID: 38626311 PMC: 11135649. DOI: 10.1093/cvr/cvae068.

Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR.

Murugesan P, Zhang Y, Huang Y, Zong N, Youn J, Chen W Circ Res. 2024; 134(4):351-370.

PMID: 38299369 PMC: 10880947. DOI: 10.1161/CIRCRESAHA.123.323090.

Defining the clinical validity of genes reported to cause pulmonary arterial hypertension.

Welch C, Aldred M, Balachandar S, Dooijes D, Eichstaedt C, Graf S Genet Med. 2023; 25(11):100925.

PMID: 37422716 PMC: 10766870. DOI: 10.1016/j.gim.2023.100925.

Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice.

Kelly N, Chan S Rev Cardiovasc Med. 2023; 23(11).

PMID: 36875282 PMC: 9980296. DOI: 10.31083/j.rcm2311378.

Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension.

Ryanto G, Musthafa A, Hara T, Emoto N Int J Mol Sci. 2023; 24(4).

PMID: 36834742 PMC: 9963072. DOI: 10.3390/ijms24043332.

References

Voelkel N, Cool C, Lee S, Wright L, Geraci M, Tuder R . Primary pulmonary hypertension between inflammation and cancer. Chest. 1998; 114(3 Suppl):225S-230S. DOI: 10.1378/chest.114.3_supplement.225s. View

Brock T, McNish R, Peters-Golden M . Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999; 274(17):11660-6. DOI: 10.1074/jbc.274.17.11660. View

Peacock A . Primary pulmonary hypertension. Thorax. 1999; 54(12):1107-18. PMC: 1763750. DOI: 10.1136/thx.54.12.1107. View

Ermert L, Ermert M, DUNCKER H, Grimminger F, Seeger W . In situ localization and regulation of thromboxane A(2) synthase in normal and LPS-primed lungs. Am J Physiol Lung Cell Mol Physiol. 2000; 278(4):L744-53. DOI: 10.1152/ajplung.2000.278.4.L744. View

Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T . BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol. 2000; 221(1):249-58. DOI: 10.1006/dbio.2000.9670. View

Deng Z, Morse J, Slager S, Cuervo N, Moore K, Venetos G . Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000; 67(3):737-44. PMC: 1287532. DOI: 10.1086/303059. View

Lane K, Machado R, Pauciulo M, Thomson J, Phillips 3rd J, Loyd J . Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26(1):81-4. DOI: 10.1038/79226. View

Thomson J, Machado R, Pauciulo M, Morgan N, Humbert M, Elliott G . Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000; 37(10):741-5. PMC: 1757155. DOI: 10.1136/jmg.37.10.741. View

Machado R, Pauciulo M, Thomson J, Lane K, Morgan N, Wheeler L . BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2000; 68(1):92-102. PMC: 1234937. DOI: 10.1086/316947. View

10.

Zhang Y, Walker J, Huang A, Keaney J, Clish C, Serhan C . Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem J. 2002; 361(Pt 2):267-76. PMC: 1222306. DOI: 10.1042/0264-6021:3610267. View

11.

Zhao G . Consequences of knocking out BMP signaling in the mouse. Genesis. 2002; 35(1):43-56. DOI: 10.1002/gene.10167. View

12.

Jeffery T, Morrell N . Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2003; 45(3):173-202. DOI: 10.1053/pcad.2002.130041. View

13.

Lee M, Yang C, Jin D, Chang Y, Bang B, Kim Y . Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. J Immunol. 2003; 170(5):2557-63. DOI: 10.4049/jimmunol.170.5.2557. View

14.

Runo J, Loyd J . Primary pulmonary hypertension. Lancet. 2003; 361(9368):1533-44. DOI: 10.1016/S0140-6736(03)13167-4. View

15.

Dorfmuller P, Perros F, Balabanian K, Humbert M . Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003; 22(2):358-63. DOI: 10.1183/09031936.03.00038903. View

16.

Cogolludo A, Moreno L, Bosca L, Tamargo J, Perez-Vizcaino F . Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circ Res. 2003; 93(7):656-63. DOI: 10.1161/01.RES.0000095245.97945.FE. View

17.

Jones J, Walker J, Song Y, Weiss N, Cardoso W, Tuder R . Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2004; 286(5):H1775-84. DOI: 10.1152/ajpheart.00281.2003. View

18.

West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J . Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004; 94(8):1109-14. DOI: 10.1161/01.RES.0000126047.82846.20. View

19.

Simonneau G, Galie N, Rubin L, Langleben D, Seeger W, Domenighetti G . Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S):5S-12S. DOI: 10.1016/j.jacc.2004.02.037. View

20.

Newman J, Trembath R, Morse J, Grunig E, Loyd J, Adnot S . Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004; 43(12 Suppl S):33S-39S. DOI: 10.1016/j.jacc.2004.02.028. View